Pharmacoeconomic analysis of SARS-CoV-2 infection treatment
https://doi.org/10.34215/1609-1175-2025-3-61-66
Abstract
Objective. To analyze the financial burden of coronavirus infection in hospital settings, taking into account clinical and statistical groups (CSG), as well as an assessment of its costs for 2020–2023. Materials and methods. The calculation of payment for patient treatment was carried out for four CSGs, taking into account the average length of hospitalization. It was 12, 14, 17, and 24 days in cases of mild, average, severe, and extremely severe course of the disease, respectively. The tariff distribution was as follows: 69% to wages, 14% to the purchase of medicines, 13% to additional inventory, and 4% to food. Results. In 2021, the total economic burden comprised 404,810,111.27 RUB. Expenditures on wages amounted to 284,908,611.22 RUB, medicines – 56,673,415.55 RUB, inventory – 52,625,314.43 RUB, food – 10,602,770.07 RUB. Under the total number of cases of 2235 in 2022, the total economic burden amounted to 370,067,971.31 RUB. In this number, wages accounted for 255,346,900.2 RUB, medicines – 51,809,516 RUB, soft inventory – 48,108,836.27 RUB, food – 14,802,718.84 RUB. In 2023, the total number of cases was 2033, and the economic burden amounted to 308,515,244.25 RUB. The share of wages was 212,875,587.75 RUB, medicines – 43,192,148.24 RUB, inventory – 40,106,994.79 RUB, and food – 12,340,613.78 RUB. Conclusion. According to the data obtained, the economic burden of inpatient treatment of patients with confirmed coronavirus infection associated with SARS-CoV-2 in the State Budgetary Healthcare Institution Regional Clinical Hospital No. 2 over three years amounted to 1,083,393,427.14 RUB under the total number of cases in different clinical and statistical groups of 6932.
About the Authors
S. A. Sokotun
Pacific State Medical University
Russian Federation
Russian Federation
Svetlana A. Sokotun, Cand. Sci. (Med.), Associate Professor of the Department of Infectious Diseases
2 Ostryakova ave., Vladivostok, 690002, Russia
A. O. Mikhailov
Pacific State Medical University
Russian Federation
Russian Federation
Vladivostok
A. I. Simakova
Pacific State Medical University
Russian Federation
Russian Federation
Vladivostok
S. N. Beniova
Regional Clinical Hospital No. 2
Russian Federation
Russian Federation
Vladivostok
N. G. Plekhova
Pacific State Medical University
Russian Federation
Russian Federation
Vladivostok
A. V. Martynova
Pacific State Medical University
Russian Federation
Russian Federation
Vladivostok
References
1. Ignatyeva VI, Avksentyeva MV. Analysis of methodological features of studies on the socio-economic burden of diseases in the Russian Federation in the context of developing a standard methodology for analyzing the cost of disease for the purpose of its use in assessing healthcare technologies. Pharmakoeconomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2014;7(3):3–11 (In Russ.).
2. Ivanova MZ, Zhurtova IB, Sizhazheva SKh, Gubachikova AM. Predictors of severe disease course and high mortality in patients with COVID-19 and diabetes mellitus. Pharmateka. 2021;28(4):10–15 (In Russ.). doi: 10.18565/pharmateca.2021.4.10-15
3. Petrosyan GA, Petrosyan IB, Petrosyan EG. Unevenness of the economic consequences of the COVID-19 pandemic: the depth of the economic decline in different countries and the factors that caused it. Studies on Russian Economic Development. 2023;4:181–196 (In Russ.). doi: 10.47711/0868-6351-199-181-196
4. Kaira AN, Svitich OA, Murzina AA. Epidemiological features of the age-gender spread of the incidence of coronavirus infection COVID-19 and mortality (review). Sanitary Doctor. 2021;7:18–31 (In Russ.). doi: 10.33920/med-08-2107-02
5. Temporary guidelines: prevention, diagnosis, and treatment of the new coronavirus infection (COVID-19). (Developer of the clinical guideline: Academician V.I. Pokrovsky National Association of Infectious Disease Specialists) Ministry of Health of the Russian Federation, Moscow, 2023. (In Russ.). URL: http://disuria.ru/_ld/13/1343_C19PDL261023N18.pdf (Accessed March 23, 2023).
6. Malinnikova EYu. New coronavirus infection. Today's look at the pandemic of the XXI century. Infectious Diseases: News. Opinions. Training. 2020;9(2):18–32 (In Russ.). doi: 10.33029/2305-3496-2020-9-2-18-32
7. Markelova OA. et al. Features of the clinical picture of patients with COVID19 hospitalized in a multidisciplinary somatic hospital. Bulletin of Medical University "Reaviz": Rehabilitation, Doctor and Health. 2021;5(53):23–33 (In Russ.). doi: 10.20340/vmi-rvz.2021.5.COVID.2
8. Shishkin SV, Ponkratova OF. Territorial Disparity between Tariff ’s for Medical Care in the Compulsory Health Insurance. Public Administration Issues. 2021;1:75–99 (In Russ.).
9. Starodubov VI, Kadyrov FN, Obukhova OV, Mitroshin PV, Chililov AM, Kobyakova OS. Payment methods for primary health care, specialized (including high-tech) medical care in the compulsory health insurance system: the logic of the most urgent changes in the tariff policy of 2023. Manager Zdravoochranenia. 2023;6:4–13 (In Russ.). doi: 10.21045/1811-0185-2023-6-4-13
10. Omelyanovsky VV et al. Methodological problems of cost analysis of a disease. Medical Technologies. Assessment and Choice. 2011;1:42–50 (In Russ.).
11. Yagudina RI et al. Pharmacoeconomics and drug provision: cardiovascular diseases: Textbook. Rostov-on-Don: Phoenix, 2019 (In Russ.).
12. Duganov MD. Evaluation of the effectiveness of health care expenditures at the regional and municipal levels. Scientific works of the Foundation "E.T. Gaidar Institute for Economic Policy". 2007;105:1–112 (In Russ.).
Review
For citations:
Sokotun S.A., Mikhailov A.O., Simakova A.I., Beniova S.N., Plekhova N.G., Martynova A.V. Pharmacoeconomic analysis of SARS-CoV-2 infection treatment. Pacific Medical Journal. 2025;(3):61-66. (In Russ.) https://doi.org/10.34215/1609-1175-2025-3-61-66
Views:
22
Email this article 